Macular hole formation following intravitreal injection of ranibizumab for branch retinal vein occlusion: a case report

BMC Research Notes

Masahiro Miura²  Hiroshi Goto¹  Takuya Iwasaki²  Ryosuke Mitsuhashi²  Daisuke Muramatsu² 

[1]Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan

[2]Tokyo Medical University, Ibaraki Medical Center, 3-20-1 Chuo, Ami-machi, Inashiki-gun 300-0395, Ibaraki, Japan

关键词: Complication;    Macular edema;    Ranibizumab;    Macular hole;    Branch retinal vein occlusion;   

Others  :  1230878
DOI  :  10.1186/s13104-015-1324-4

 received in 2015-04-01, accepted in 2015-08-11,  发布年份 2015

【 摘 要 】

Background

Macular hole formation after anti-vascular endothelial growth factor therapy is a rare complication. We report macular hole formation after intravitreal ranibizumab injection for branch retinal vein occlusion.

Case presentation

A 63-year-old Asian male was treated with intravitreal ranibizumab injection for chronic macular edema with branch retinal vein occlusion in his right eye. Before treatment, best-corrected visual acuity in his right eye was 20/200. Nine days after injection, a full thickness macular hole developed with reduction of macular edema. After pars plana vitrectomy combined with cataract surgery, the macular hole was successfully closed, and the best-corrected visual acuity in his right eye improved to 20/40.

Conclusion

The possibility of an infrequent complication like macular hole should be considered for intravitreal ranibizumab for macular edema with branch retinal vein occlusion.

【 授权许可】

   
2015 Muramatsu et al.

【 图 表 】

Fig.1.

【 参考文献 】

• [1]The Branch Vein Occlusion Study Group: Argon laser photocoagulation for macular edema in branch vein occlusion Am J Ophthalmol 1984, 98:271-282.
• [2]Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M: SCORE Study Research Group: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009, 127:1115-1128.
• [3]Okunuki Y, Usui Y, Katai N, Kezuka T, Takeuchi M, Goto H, Wakabayashi Y: Relation of intraocular concentrations of inflammatory factors and improvement of macular edema after vitrectomy in branch retinal vein occlusion. Am J Ophthalmol 2011, 151:610-616.
• [4]Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG: BRAVO Investigators: Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010, 117:1102-1112.
• [5]Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R: GALILEO Study Group: Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol 2014, 158:1032-1038.
• [6]Rosenfeld PJ, Fung AE, Puliafito CA: Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central vein occlusion. Ophthalmic Surg Lasers Imaging 2005, 36:336-339.
• [7]Miura M, Iwasaki T, Goto H: Macular hole formation after intravitreal bevacizumab administration in a patient with myopic choroidal neovascularization. Retin Cases Brief Rep 2011, 5:149-152.
• [8]Moisseiev E, Goldstein M, Loewenstein A, Moisseiev J: Macular hole following intravitreal bevacizumab injection in choroidal neovascularization caused by age-related macular degeneration. Case Rep Ophthalmol 2010, 1:36-41.
• [9]Querques G, Souied EH, Soubrane G: Macular hole following intravitreal ranibizumab injection for choroidal neovascular membrane caused by age-related macular degeneration. Acta Ophthalmol 2009, 87:235-237.
• [10]Grigoropoulos V, Emfietzoglou J, Nikolaidis P, Theodossiadis G, Theodossiadis P: Full-thickness macular hole after intravitreal injection of ranibizumab in a patient with retinal pigment epithelium detachment and tear. Eur J Ophthalmol 2010, 20:469-472.
• [11]Cho JH, Park SE, Han JR, Kim HK, Nam WH: Macular hole after intravitreal ranibizumab injection for polypoidal choroidal vasculopathy. Clin Exp Optom 2011, 94:586-588.
• [12]Nagpal M, Mehta V, Nagpal K: Macular hole progression after intravitreal bevacizumab for hemicentral retinal vein occlusion. Case Rep Ophthalmol 2011.
• [13]Forooghian F, Kertes PJ, Eng KT, Agrón E, Chew EY: Alterations in the intraocular cytokine milieu after intravitreal bevacizumab. Invest Ophthalmol Vis Sci 2010, 51:2388-2392.
• [14]Nakao S, Ishikawa K, Yoshida S, Kohno R, Miyazaki M, Enaida H, Kono T, Ishibashi T: Altered vascular microenvironment by bevacizumab in diabetic fibrovascular membrane. Retina 2013, 33:957-963.
• [15]Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L, Eid Farah M, Pieramici DJ, Berrocal MH, Sanchez JG: Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008, 92:213-216.